FOLH1 and prostate cancer: The use of molecular images in patients with prostate cancer has been fundamental in the diagnosis, follow-up, prognosis and treatment of patients, especially with radiotracers that bind to prostate-specific membrane antigen such as 18F-PSMA-1007 or 68Ga-PSMA, which have been recommended by different guidelines as an adequate method to evaluate prostate, lymph node and bone involvement in order to provide the greatest therapeutic benefit, including therapy with 177Lu-PSMA, which in recent years has shown an increase in the overall survival (20, 21).